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Abstract
Vaccines that elicit protective cytotoxic T lymphocytes (CTL) may improve on or augment those designed primarily to elicit
antibody responses. However, we have little basis for estimating the numbers of CTL required for sterilising immunity at an
infection site. To address this we begin with a theoretical estimate obtained from measurements of CTL surveillance rates
and the growth rate of a virus. We show how this estimate needs to be modified to account for (i) the dynamics of CTL-
infected cell conjugates, and (ii) features of the virus lifecycle in infected cells. We show that provided the inoculum size of
the virus is low, the dynamics of CTL-infected cell conjugates can be ignored, but knowledge of virus life-histories is
required for estimating critical thresholds of CTL densities. We show that accounting for virus replication strategies increases
estimates of the minimum density of CTL required for immunity over those obtained with the canonical model of virus
dynamics, and demonstrate that this modeling framework allows us to predict and compare the ability of CTL to control
viruses with different life history strategies. As an example we predict that lytic viruses are more difficult to control than
budding viruses when net reproduction rates and infected cell lifetimes are controlled for. Further, we use data from acute
SIV infection in rhesus macaques to calculate a lower bound on the density of CTL that a vaccine must generate to control
infection at the entry site. We propose that critical CTL densities can be better estimated either using quantitative models
incorporating virus life histories or with in vivo assays using virus-infected cells rather than peptide-pulsed targets.
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Introduction
The majority of vaccine design approaches to date have used
neutralizing antibody titers as a correlate of efficacy. However,
major infectious diseases such as HIV-AIDS, TB and Malaria
have not yet fully yielded to vaccines aimed at eliciting antibodies.
There is currently much interest in developing vaccines that also
elicit pathogen-specific CD4 T cells or, more commonly, CD8 T
cells (also known as cytotoxic T lymphocyte, or CTL). Such
vaccines need to generate T cells of sufficient functional quality,
appropriate tissue tropism, and in sufficient numbers. Manipulat-
ing all three features of the CTL response presents a major
challenge that requires understanding of the biology of T cell
priming and the cells’ interactions with their microenvironment
during clonal expansion and contraction. However, assuming the
first two features can be optimised, the third raises an important
question – how many T cells does a vaccine need to generate in
order to protect against infection? This of course might be
determined empirically in animal models, but another approach is
to search for principles that might guide our intuition for human
vaccine design.
A CTL response is a dynamic process whose chance of success
may depend on precursor frequency, speed of priming and clonal
expansion or reactivation, total cell numbers, access to infected
tissues, and the rate and efficiency with which they survey
potentially infected cells. Mathematical models can help us
develop a quantitative understanding of how these processes
influence the potential for protection. In this paper we focus on
tissue-resident activated CTL and the challenges they face in
eliminating a growing population of virus-infected cells, with an
emphasis on how virus replication strategies influence the
efficiency of CTL surveillance.
Results
The standard model predicts critical thresholds for CTL
immunity
What we present here builds on the standard model of virus
growth used extensively in the literature (see, for example, refs [1–
9]). In the standard model the dynamics of infection in a tissue can
be described by the abundance of infected cells I(t). During early
stages of an infection when susceptible cells are in abundance, and
in the absence of specific immunity, I(t) grows exponentially as
exp(rt) (the doubling time D is then (log2)=r). The parameter r is
the per capita growth rate of the infected cell population and is the
net outcome of a plethora of biological processes; virus replication,
shedding from infected cells, clearance of virus from the
intercellular space, infection of susceptible cells; and loss of
infected cells by natural mortality, virus-induced mortality and
innate immune mechanisms. Now suppose in addition that
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CTL are tissue-resident and activated, CTL and infected cells are
well-mixed, distributed spatially randomly, and a CTL encounters
other cells with a constant probability per unit time. These
assumptions yield a mass-action term for the killing of infected cells
by CTL,
dI
dt
~rI{kCI ð1Þ
where I and C are the densities of infected cells and CTL
respectively. We define density to be a dimensionless quantity in
the range ½0,1 . It represents cell numbers locally as a fraction of all
of the cells being surveyed by CTL, uninfected or infected. We use
this definition (rather than cells per unit volume of tissue, cells per
unit volume of blood, or the proportion of CTL that are antigen-
specific) because it relates directly to cell frequencies obtained from
tissue samples by flow cytometry, and it yields a simple
interpretation of the parameter k, which we return to in a
moment.
In this model, sterilising immunity corresponds to a net growth
rate dI=dtv0. To achieve this requires specific CTL to be present
above a critical density C  where
C ~r=k: ð2Þ
With our dimensionless definition of density, the parameter k is
the rate of surveillance, or the expected number of cells of any kind
that a CTL encounters per unit time; 1=k is the expected time
between contacts; and kI, where I is the range ½0,1 , is the
expected number of infected cells that a single CTL encounters
per unit time (in Text S1 we discuss how this interpretation of k
relates to its interpretation when C and I are measured as
numbers of cells per unit volume). So if in the absence of CTL,
infected cells double in number every D days, a simple estimate of
the local density of CTL required to control the infection is
C ~
log2
Dk
: ð3Þ
However, this simple model neglects at least two major biological
processes that may impact the estimate of the critical density – the
dynamics of CTL-infected cell conjugates, and the life history of
viruses within infected cells. We investigate these separately, and
begin with the influence of CTL-target handling time on the rate
at which a population of CTL kills a fixed number of target cells.
The dynamics of CTL-infected cell conjugates
The mass-action killing term implies that killing is instantaneous
on encounter of a CTL with an infected cell. However, CTL take
time to lyse and detach from their targets. Mempel et al. [10]
showed that CTL engaged in lysis can remain bound for up to half
an hour after initial contact. Thus accounting for the temporary
sequestration of CTL in conjugation with infected cells may be
important for the dynamics of killing and for assessing the validity
of the mass-action assumption.
A simple way to include the time take for CTL to handle
infected cells is to explicitly track CTL-infected cell conjugates [11],
such that free CTL (C) initially present at density C0 successfully
bind to infected cells present at density I at rate kI per CTL, and
remain in conjugates X for a mean time 1=n. This time can be a
compound of several distinct processes – delivery of the lethal hit
following conjugation, release of the apoptotic cell, and a possible
recovery time before the CTL is capable of detecting another
infected cell. Here k is the rate of surveillance of all cell types, and
incorporates any time spent conjugated with uninfected cells.
dC
dt
~{kCIznX ð4Þ
dX
dt
~kCI{nX ð5Þ
dI
dt
~{kCI ð6Þ
Since if we assume no loss of CTL the number of bound complexes
X~C0{C, X can be eliminated to give
dC
dt
~{(kIzn)CznC0 ð7Þ
dI
dt
~{kCI ð8Þ
We can now identify the conditions under which mass-action holds.
If CTL are in excess (C0&I), then C(t)^C0 and so mass-action
holds for all n and k, irrespective of handling or search times.
If infected cells are in excess, three regimes exist:
1. When search times are small compared to handling times, or
n%kI, C(t) approaches the following at exponential rate kI:
C(t)~
nC0
kI(t)zn
ð9Þ
which yields
dI
dt
~{
nkIC0
kIzn
^{nC0 ð10Þ
In this regime, the rate of cell loss is limited by the handling
time 1=n and the CTL frequency C0, and the infected cell
density declines linearly with time in the absence of replication.
Author Summary
In the search for vaccines that provide reliable protection
against major diseases such as HIV-AIDS, TB and Malaria,
there is now a focus on generating populations of antigen-
specific cytotoxic T lymphocytes (CTL), immune cells that
recognise and kill infected cells. However, we have little
idea of the number or density of CTL a vaccine would need
to elicit to provide sterilizing immunity to an infection in a
given tissue. In this study we use mathematical models to
understand how a virus’s replication strategy influences
the minimum density of CTL needed to provide immunity
at an infection site. We show that traditional models that
neglect the viral lifecycle within infected cells will
underestimate this density. To illustrate, we use our
modelling framework to estimate the CTL density needed
to control the spread of virus at the very earliest stages of
primary SIV infection in rhesus macaques.
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infected cells reach a non-zero steady state and clearance is not
possible.
2. When handling and search times are comparable (n^kI), an
analytic solution is not possible, but we can describe the
dynamics of clearance. At t~0, all CTL are unbound and so
the rate of loss of infected cells is maximal, with per capita rate
kC0. CTL are then progressively sequestered in conjugates; the
killing rate falls, to a minimum kCmin at t*1=n where Cmin is
the solution to dC=dt~0 and d2I=dt2~0, which yields
Cmin=C0~
n
kIzn
*
n
kI0zn
; ð11Þ
so if kI~n, the killing rate is halved at t*1=n; then for tw1=n ,
as infected cells become scarce, the number of free CTL
progressively returns to C0 and we approach mass-action
killing using total CTL density C0 (that is, dI=dt^{kC0I) for
t&1=n.
3. When handling times are short compared with search times
(n&kI), then
dC
dt
^n(C0{C) ð12Þ
which rapidly equilibrates at C~C0 and the loss of infected
cells again obeys mass-action, dI=dt~{kC0I.
Considering the dynamics of surveillance and of CTL-target
conjugates may resolve some of the discord between microscopy
studies showing extended encounter times between CTL and their
targets [10] and simple mass-action models of in vivo surveillance
and killing by CTL, all of which describe experimental data well
using the assumption of instantaneous killing and yield estimates of
1–40 cells surveyed per CTL per minute [8,9,12,13]. Extended
encounter times between CTL and infected cells are consistent
with these models if CTL are in excess. At high ratios of CTL to
infected cells (usually referred to in the literature as the
effector:target ratio, E:T), few CTL will kill more than once,
and so handling time becomes irrelevant for the long-term
dynamics of infected cell removal.
So if the inoculum size of the virus is low compared to existing
effector cell densities (E : T&1), or if handling times are short
compared to the time taken to survey cells, we do not need to
consider the dynamics of CTL-infected cell conjugates to calculate
the minimum density of specific CTL needed for protection.
The influence of virus life history strategies on killing
dynamics
CTL are triggered by their recognition of peptides derived from
virus proteins generated within the infected cell and presented on
MHC class I molecules. Existing estimates of the surveillance rate
k [8,9,12,13] use the assumption that the infected cells are
expressing peptide-MHC complexes at a constant level over the
timecourse of the experiments. However, viral replication is a
dynamic process and so the window of expression of a given
peptide-MHC complex by a cell infected with a live virus may be
limited. Thus CTL have to contend with not only locating cells
within a tissue, but also the dynamics of the expression of viral
epitopes [14].
In the model that follows we assume we are in a regime where
mass-action operates. In Text S2 we describe the more general
model in which both handling time and virus epitope dynamics are
accounted for.
How will the dynamics of virion production and virus epitope
expression affect our estimate of the local density of CTL required
for sterilising immunity, C ? With the mass-action assumption, the
population dynamics of infected cells I becomes
LI
Lt
z
LI
La
~{ k(a)Czm(a) ðÞ I(a,t) ð13Þ
I(a~0,t)~ 
ð?
0
m(a)I(a,t)da ð14Þ
where I(a,t) is the density of cells at time t that have been infected
for a time a, m(a) is the rate of release of virions at age a after
infection, m(a) is the age-dependent mortality of infected cells not
ascribed to CTL activity, and C is the (now assumed time-
independent) free CTL density. This equation describes the
dynamics of infected cell numbers in infinitesimal age classes as
they are generated through new infection, age and die. Since
detection upon encounter is dependent on the expression of the
appropriate virus epitopes and hence on time since infection, the
rate at which a CTL encounters and recognises infected cells in
age class a is now k(a)I(a), and
Ð
k(a)I(a,t)da is the total rate at
which a CTL encounters and recognises infected cells. Equation
(14) represents the process of new infections, and assumes (i)
susceptible cells are in abundance, and (ii) that infection of new
cells or clearance of free virus is more rapid than the dynamics of
virus replication and release from infected cells. So the rate of
infection of susceptible cells at time t is proportional to the total
rate of virus production at that time, with constant of
proportionality  .
A useful quantity is the survivorship ‘(a), the proportion of a
cohort of cells that are still alive at a time a after they were
infected. The survivorship is related to the total mortality
m(a)zk(a)C through
‘(a)~exp {
ða
0
(m(s)zk(s)C)ds
  
: ð15Þ
The steady state age-distribution solution of equation (14) yields
the total cell population growing or declining as exp(rt), where r
satisfies the Lotka-Euler equation (see Text S3 for a derivation)
 
ð
‘(a)m(a)e{rada~1: ð16Þ
This has a unique real solution for the growth rate r [15].
We consider representations of two replication strategies – a
budding virus, which after some delay following infection sheds
virions from the host cell at a constant rate, with a possible
increased burden of mortality for the host cell; and a lytic virus,
which replicates in the host cell without release of virions until it
lyses the host cell, releasing all its progeny within a short time
interval.
For both strategies we need to know three functions. These
describe the visibility to CTL, the virus production rate and the
virus-induced mortality as functions of age since infection, and are
shown schematically in Figure 1.
In our representations of these strategies we have made the
simplifying assumption that above a certain threshold of epitope
expression, an infected cell is capable of being identified by CTL
at constant rate k. A biological motivation for this is that CTL can
Virus Replication Strategies and Control by CTL
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the efficiency of recognition to saturate quickly in peptide density.
With the forms for the virus-induced mortality described in
Figure 1, and k, exact expressions can be derived for the
survivorship ‘(a). For budding viruses, we assume that infected
cells become visible to CTL before the onset of virus-induced
mortality acvam (Figure 1), but our conclusions are independent
of the ordering of these events. We then have
‘bud(a)~
1 aƒac
exp {kC(a{ac) ðÞ acvaƒam
exp {kC(a{ac){m(a{am)
  
awam
:
8
> <
> :
ð17Þ
For lytic viruses,
‘lytic(a)~
1 aƒac
exp {kC(a{ac) ðÞ acƒaƒam
exp {kC(a{ac){m(a{am)
  
amƒaƒalysis
0 awalysis
8
> > > <
> > > :
ð18Þ
For the budding virus, solving equation 16 for the steady state
growth rate r reduces to solving the following implicit equation for
r,
e{ram~
kCzmzr
 mexp {kC(am{ac){m(am{am)
   : ð19Þ
For lytic viruses it yields the direct solution
r~
ln( N){kC(alysis{ac){m(alysis{am)
alysis
: ð20Þ
Identical expressions are derived if visibility to CTL begins after
the onset of virus-induced mortality (acwam).
Comparing CTL efficacy against different virus
strategies. We can compare the effectiveness of CTL
responses against lytic and budding virus infections. For
reference we compare both to the standard model of a budding
virus that assumes infected cells have exponentially distributed
lifetimes, and immediately following infection become visible to
CTL and begin to make virus at a constant rate.
For a meaningful comparison of the three model strategies, we
choose parameters such that (i) in the absence of CTL, infected
cells have the same expected lifetime and the same net growth rate
r, and (ii) the duration of the window of opportunity for CTL to
detect infected cells before virus is released is equal in the age-
structured budding and lytic models. This is the parameter T
shown in Figure 1.
In the absence of CTL, the expected lifetime of a cell infected
with a budding virus is amz1=m. For a lytic virus it is
amz(1=m)(1{exp({m(alysis{am))). In a simple birth-death
model dI=dt~cI{dI, where new infected cells are generated at
rate cI, the expected lifetime of infected cells is 1=d and their
numbers grow at net rate r~c{d. We set the growth rate without
loss of generality to 1 day{1, and then choose parameters that
simultaneously equate the infected cell lifetimes, satisfy equations
(19) and (20), and equate the values of T for the budding
(T~am{ac) and lytic (T~alysis{ac) strategies. Figure 2 shows
the dependence of the net growth rate of infected cells on the CTL
density C for the different strategies.
We draw three conclusions here. First, if budding and lytic
viruses are visible to CTL from the time of infection, both life-
history strategies give identical results to the simple birth-death
model. If there is any delay in infected cells becoming visible to
CTL, the threshold CTL frequency required for immunity
increases.
Second, if we control for growth rate, infected cell lifetime and
the CTL window of opportunity T, a lytic strategy is harder to
control than a budding strategy. This is perhaps counterintuitive at
first; one might expect that removal of a cell infected with a lytic
virus removes all the potentially infective virions and thus would
have a more significant impact on slowing the spread of infection
than the removal of a continuously-shedding infected cell.
However, the result can be understood simply; with these
constraints, the cell infected with a lytic virus is visible to CTL
for a smaller proportion of its replicative cycle. With equal
expected lifetimes and growth rates, the average rate of production
Figure 1. Schematic representation of budding and lytic virus replication strategies. On the left, budding viruses: a time ac after
infection of the cell, sufficient epitopes are presented on the cell surface for CTL to recognise and kill the cell; virion production causes an increase in
cell mortality, m, at a later time am; and at a later time am, virions begin to be shed from the cell at constant rate m. On the right, lytic viruses:
beginning a time ac after infection the cell becomes visible to CTL, after time am, stress induced by virus replication within the cell generates an
additional mortality rate m; and the infected cell bursts and releases N virions a time alysis after infection. In both figures, T is the duration of a cell’s
visibility to CTL before virus release begins. Intervals between events are not shown to any scale.
doi:10.1371/journal.pcbi.1002274.g001
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a CTL killing a lytic-virus-infected cell prevents fewer virions
being released than when killing a cell infected with a budding
virus.
Our third conclusion is that to make a parameter-independent
comparison meaningful requires controlling for the growth rate,
cell lifetime and CTL visibility window T, as well assuming equal
k for the two strategies. Relaxing these constraints and allowing
the parameters to vary then moves from the general to the specific,
and for a given pair of virus life-histories the lytic versus budding
conclusion above may be reversed. Given the parameters
governing different virus replication strategies, this framework
allows us to predict and compare the abilities of CTL to control
them.
Example: What CTL density is needed to control acute SIV
infection?
SIV in rhesus macaques buds from its primary target cell
population, CD4 T cells. Infection may begin at a mucosal surface
and virus remains localised there for 2–7 days before disseminating
to other tissues [17,18], followed by rapid exponential growth of
virus titers in blood. Eventually a combination of mechanisms
(CTL removal of infected cells, virus cytopathicity, innate
immunity, the availability of susceptible cells, and antibody
responses) brings virus growth under control and the infection
enters the chronic phase. Here we use data from acute SIV
infection to estimate the minimum density of tissue-resident CTL
that a vaccine needs to elicit for early control of infected cell
growth at the site of infection. We assume that the inoculum size is
small, and so E:T will be large. In this regime we argue that
handling time can be neglected, and that the mass-action
approximation is valid. We assess the validity of the E:T
assumption following the analysis below.
Estimating the critical killing rate kC . We assume that
the cytopathic effects of SIV begin upon virus shedding
(am~am~t). The growth rate r0 of the infected cell population
when susceptible cells are in abundance is given implicitly by
equation 19,
e{r0t~
kCzmzr0
 me{kCT : ð21Þ
In what follows, we assume that both the natural mortality of
cells and the contribution of the endogenous CTL response to
infected cell death in the first few days of acute infection are
negligible. The combined process of presentation of SIV epitopes
to naive CTL in local lymph nodes, activation, proliferation and
migration of CTL to the infection site is likely to take several days;
and similar upslopes of virus load are observed in SIV-infected
rhesus macaques in the presence or absence of CD8 responses
[19], although CTL likely make a substantial contribution to
limiting peak viremia [19–22]. We therefore assume that cell death
at the site of virus entry in the first week of infection is due mainly
to non-CTL mechanisms such as innate immunity and viral
cytopathicity, and so we assume C~0 in unvaccinated individuals.
Figure 2. Dependence of infected cell growth rates on CTL numbers, for different virus replication strategies. We compare the
standard model (green) with models of a budding virus (black) and lytic (red) strategies. Parameters are chosen so that in the absence of CTL all
models yield the same infected cell growth rate, expected lifetime, and for the lytic and budding strategies have the same window of visibility of
infected cells to CTL, T, before virus release begins. Parameter choices; growth rate in absence of CTL is r~1 day{1, equivalent to a doubling time of
16 hours; expected infected cell lifetime is 2 days; T~1:2 day; onset of virus shedding in the budding virus model is at 1:5 days; death rate due to
cytopathicity of lytic virus, m~0:1 day{1;  ~0:01 (new infected cells per virion).
doi:10.1371/journal.pcbi.1002274.g002
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CD4 depletion in the gut lamina propria in SIV infection and
showed that local infected cell densities doubled between days 6
and 7 post-inoculation (from *2:5{5 cells mm{2), correspond-
ing to a net exponential growth rate of r0^ln2~0:7 day{1. The
death rate of infected CD4+ T cells could be estimated following
depletion of uninfected cells locally, at around 28 days post-
infection, and found to be approximately 0:2 day{1 (half-life *4
days). A caveat here is that at this relatively late stage of acute
infection this figure very likely includes the contribution of
adaptive immune responses to cell death. So it likely overestimates
the death rate of infected cells in the first week of infection.
Now suppose that a vaccine can generate a local SIV-specific
memory CTL density, C. What is the critical value kC needed to
reduce the acute growth rate to zero? Using equation (21) with
C~0 and the parameter estimates from primary SIV infection
above, we can eliminate the unknown quantity  m and obtain
1~
mzkC 
(mzr0)exp(r0t{kC T)
: ð22Þ
We assume shedding begins t~24h post infection [24] and that an
infected cell becomes visible to CTL 6–12 hours post infection,
depending on the epitope being expressed. We solve (22)
numerically to calculate a distribution of estimates of kC , using
flat priors on the uncontrolled growth rate r0[(0:3,1)day{1,
infected cell death rate m[(0:05,0:5) day{1, and the CTL window
duration T[(12,18) h. We obtain the median value kC  =0.8
day{1 (IQR 0.6–1.1). Thus the CTL elicited by a vaccine must
increase the infected cell death rate at least 2-fold (IQR 1.0–4.1).
We can assess the importance of modeling virus epitope
dynamics by comparing these estimates of kC  to those of the
standard model in which kC ~r0. To control virus growth with a
CTL response directed against an epitope first visible 6 h post
infection (T~18 h) requires an increase in the critical CTL
density of 14% (IQR 12–15) over the standard model prediction; a
response directed against an epitope visible at 12 h requires an
increase of 33% [28–38].
The quantity kC ^0:8day{1 is the minimum killing rate
required of one epitope-specific response to control infection.
However, a vaccine-induced CTL response may target multiple
epitopes. Each specific response will be able to recognise an
infected cell beginning a time t{Ti after it becomes infected, and
will then contribute a killing rate kiCi. Each may then be required
to contribute less than 0:8 day{1 to the infected cell death rate.
Timing of the CTL response. Our estimate of the critical
killing rate does not depend on the time required for reactivation
and/or migration of tissue resident of SIV-specific CTL to the site
of infection. It is also independent of inoculum size, provided
E : Tw1 as required by the assumptions of the model. This
independence arises because all rates of growth and death are
linear in infected cell numbers. In fact, a delay in the onset of CTL
activity allows the growing population of infected cells to approach
the steady-state age distribution required for our result to hold.
Nevertheless, an early-acting CTL response must act rapidly
enough to avert the systemic spread of the virus; thus
unsurprisingly it is important to induce a response that is as
large and fast-acting as possible.
CTL efficiency early and late in acute infection. To put
the estimate of 0:8 day{1 into perspective, we can compare it to
estimates of the total contribution of CTL to infected cell death
late in the acute phase of SIV infection. Ganusov and de Boer [25]
calculated bounds of 0:7{1:1 day{1 for killing by CTL specific
for the KP9 epitope of Gag near the peak of acute infection of
rhesus macques with SIV. Mandl et al. [26] obtained a
comparable estimate of 0:3{0:9 day{1 for the response to Tat
epitopes. Since there are likely multiple epitopes being targeted,
these figures are lower bounds on the total CTL-mediated killing
rate. This rate is then much larger than our estimate of the total
CTL killing rate required at the entry site.
These observations suggest that the challenge CTL face in
controlling the spread of virus after systemic dissemination is far
more severe than the one they face at the infection site. There are
several possible reasons for this. First, infected cells are spatially
localised. Second, resting CD4 T cells are likely the primary target
cell population early in infection, and these cells produce virus at a
substantially lower rate than the activated CD4 T cells that are the
major source of virus in the disseminated acute phase [27]. Third,
progressive exhaustion of CTL likely reduces per-CTL surveil-
lance or killing rates later in infection.
Estimating the critical CTL density. As a step further,
knowing the required vaccine-induced cell death rate kC 
immediately gives us a lower bound on C  if we know the
surveillance rate k – the rate that a single CTL moves between
potential targets – at the entry site. The value of k is currently
unknown, although we can place broad bounds on it using
estimates from other in vivo model systems. Direct estimates have
been derived from killing of non-replicating cells pulsed with
LCMV-derived peptides, in mouse spleens [8,9], yielding k in the
range 1{5 min{1 per CTL; again for LMCV in mice using
longitudinal blood measurements [12], giving a higher estimates of
k in the spleen in the range 18{35 min {1 for acute infection,
and 8{18 min {1 in chronic infection; and for polyoma virus
[13] using peptide-pulsed splenocytes, k^4 min{1 in acute
infection and ^2 min {1 in chronic infection. (Notably, these
studies consistently conclude that the per-cell rate of surveillance
and killing of CTL is reduced in chronic infection). Using bounds
of k~1{40 cells/minute, kC ^0:8 day{1 yields critical CTL
densities C  in the range 1:4|10{5 to 6|10{4. Despite this
uncertainty, which arises from our deliberately conservative
bounds on k, these results suggest the hopeful message that the
required CTL densities are not excessively large. Polyoma virus
[13], Influenza (Seddon, B., unpublished observations) and LCMV
can all induce memory CTL densities among total splenocytes of
at least 1%, and with the obvious caveat of differing anatomical
locations, this density is at least two orders of magnitude larger
than the predicted minimum densities of mucosa-resident SIV-
specific memory CTL required for protection.
E:T ratios in early SIV infection. We have shown that we
expect mass-action kinetics to hold if populations are well-mixed,
and either the E:T ratio is high or handling times are much shorter
than cell-cell surveillance times. In early SIV infection, the validity
of the well mixed and/or the high E:T assumptions will depend
jointly on the degrees to which infected cells and CTL are
clustered or spread diffusely across the tissue. If both populations
are well mixed, we can make a rough estimate of E:T early in SIV
infection if CTL are at the predicted critical density. We estimate
3000–10000 cells (of all types) per mm2, assuming close packing
with a center-to-center spacing 10{20mm. CTL at a density of
10{4 will then be present at 0:3{1 cells mm {2,s oE : Tw1 if
the density of infected cells is smaller than this. Li et al. [23]
measure the density of SIV RNA+ CD4 T cells at day 6 post
infection to be approximately 2:5 cells mm{2 with a doubling
time of approximately 1 day. Using the well-mixed assumption, we
would then expect E : Tw1, and so the model to be valid, until at
least day 3 or 4 post infection.
We also note that the limits of applicability of mass-action
models to killing assays are still ill-defined. Ganusov et al. [28]
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spleen, a mass-action model appears to hold for E:T ratios as low
as 0.1.
Target cell availability. If infected cells are tightly clustered
and sparsely infiltrated by CTL, one would expect the rate of
killing by CTL to be limited by the handling time once a cluster
has been located. In the well-mixed deterministic model, the total
rate of loss of infected cells will then be linear in CTL densities and
independent of infected cell numbers (equation (10)). In this
regime, the model predicts CTL will ultimately fail to control the
infection, assuming susceptible cells are abundant and accessible.
These assumptions may not hold, however. The density of
susceptible cells in healthy tissue is an upper limit to infected cell
densities in very early infection, before the influx of SIV-specific
CD4 cells that provide new targets. Resting CD4 T cells are
present at a density of 100–200 mm{2 in the vaginal mucosa
(using immunohistochemical staining of biopsies taken from
healthy rhesus macaques – Gordon S., Franchini G. (NCI),
unpublished data), meaning susceptible cells make up 1–5% of the
total cell population in the lamina propria. Li et al. [23] measure
mean peak infected cell densities of 60 cells mm{2; so if infected
cells are clustered in patches, the local availability of susceptible
cells may be a factor affecting the rate of virus spread.
All of these uncertainties emphasise that more precise estimates
for k and C  need to be obtained with assays in tissues whose
spatial organisation more closely reflects typical HIV/SIV
infection sites in oral, rectal or vaginal mucosa, and using cells
infected with live replicating virus rather than peptide-pulsed
targets.
Other outstanding problems. There are inevitably many
qualifications to this result that are specific to SIV, as well as more
general issues that we present in the Discussion. Several will tend
to increase the estimate of the critical frequency. First, as noted
above, our estimate of the infected cell death rate may be too high,
as it is taken from data at the infection site 28 days-post infection
when the primary CTL and antibody responses are likely present.
We incorporate our uncertainty in this death rate by using a wide
spread of plausible values. Second, in the early growth phase of
natural primary infection, selective pressure on the mutating virus
exerted by the developing CTL response is expected to be low. A
vaccine-induced memory CTL population will increase this
pressure. To minimise this effect, broad coverage of virus
epitopes to both early and conserved proteins is required. Third,
we neglect the longer-term effect of the early generation of latently
infected CD4 T cells that escape CTL detection, for which there is
some evidence in acute infection [29].
Other factors will act to reduce our estimate. For example, in
addition to cytolysis, CTL secrete soluble factors that may make a
substantial contribution to CTL-mediated protection in both the
acute [30] and chronic [31,32] phases. Our model includes
cytolytic effects only and so may overestimate the number of
memory CTL required to control infection. In addition, a vaccine
is likely to induce specific antibody that will further decrease the
rate of transmission of virus from cell to cell, lower the growth rate
of infected cell numbers and so lower the estimate of CTL
frequencies necessary to reduce growth to zero.
Finally, it is worth noting the difficulties in connecting rates of
surveillance and killing by a single CTL in a given tissue to
estimates of the total-body contribution of CTL to infected cell
death. The problems stem from the dimensionality of rate
constants and the implicit averaging of the effects of CTL in
different anatomical locations. For example, Wick et al [33]
estimated the rate at which individual CTL kill using blood from
HIV-infected individuals. In their terminology, P and C are the
densities of infected cells and specific CTL in units of cells per unit
volume of blood, and the rate of loss of P due to CTL is kCP.
First, with this choice of units the parameter k has units of
vol cell{1 time{1 and is no longer interpretable as a rate of
surveillance (see Text S1); rather, kP is the rate of loss of infected
cells in blood per blood CTL. Second, using their estimate of k
and measurements of P, Wick et al. conclude that each CTL in
blood kills approximately 0.7 infected cells per day. However, the
loss of infected cells in blood is the also the result of killing of
infected cells by CTL in spleen and other tissues; it is not clear how
kP obtained from blood measurements relates to per-CTL killing
rates in other anatomical locations.
Discussion
Eliciting strong cellular immune responses has the potential to
augment vaccine efficacy. To our knowledge, however, there are
currently no estimates of how many CTL any given vaccine needs
to generate, or even whether the necessary numbers are
physiologically possible. Our approach provides first-order
estimates of the required CTL densities that may inform the
design of in vivo experiments or vaccine trials.
In a vaccinated individual, the E:T ratio might be expected to
be high at the beginning of an infection. In this case we have
shown that handling times can be neglected and only the effective
rate of CTL surveillance needs to be estimated to obtain the
critical density. The effective surveillance rate combines (i) the rate
at which CTL move between (survey) cells, (ii) the timecourse of
expression of virus epitopes on infected cells, and (iii) the sensitivity
of CTL to different levels of epitope expression. We illustrated this
by estimating the critical CTL density required for the early
control of SIV infection.
We have shown that considering virus life-histories is important
for two reasons. First, using the simplest mass-action models of
CTL killing with estimates of surveillance rates underestimates the
number of CTL required to provide immunity. Second, intuition
might have suggested that CTL are more effective against lytic
viruses than budding viruses, as removing a cell infected with a
lytic virus prevents all transmission from that cell. We show that
the converse is true, after controlling for growth rate and infected
cell lifetime. Thus knowing the visibility of infected cells to CTL,
as well as the virus production schedule, is important for
calculating critical CTL densities.
There other factors and potential refinements that need to be
considered:
Explicitly combining both models
We have discussed the issues of handling time and virus epitope
dynamics separately, and have argued that only the latter needs to
be considered at high E:T ratios. When E:T is low, a model
incorporating both processes may be required. Text S2 describes
such a model, and shows how both the models considered here can
be derived from it.
Spatial effects
Simulations suggest that the assumption of a mass-action killing
rate may hold in some spatially structured environments [34].
However, as discussed for SIV, mass-action may not hold if
infected cells are clustered, which may be likely particularly if
infection takes place through cell-cell transmission; or if there is
directed motion of CTL towards infected cells driven by
chemotactic or inflammatory cues. Incorporating these factors
requires the use of spatially explicit dynamical models such as
those presented in [34–36]. Other effects may complicate the
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surrounding infected cells may provide a firebreak which limits
further transmission [37,38].
Competition between CTL for infected cells
Reasonable estimates of the maximal densities of CTL
achievable in a tissue might be the order of a few percent. Even
at very high ratios of CTL to infected cells, then, if both
populations are randomly distributed the probability of multiple
CTL binding to a single infected cell is small. However, if infected
cells exhibit clustering and/or if CTL migrate preferentially to
infected cells, multiple CTL attachments to one cell may occur
frequently [39,40] and this effect needs to be considered in the
calculation of numbers of effector cells not bound in conjugates.
Multiple epitopes and CTL specificities
A CTL response typically comprises multiple clones with
different functional quality and efficiencies of surveillance, and
specific for different virus epitopes, each potentially with different
timecourses of expression. Our analysis can be interpreted as
either describing what is required of a single epitope-specific
response, or the net effect of multiple CTL responses. In principle,
the effect of multiple CTL responses can be calculated given a
numerical and functional immunodominance hierarchy, and the
timecourses of epitope expression [41]. Without going into this
level of detail, however, it is very likely advantageous for a vaccine
to induce a dominant CTL response to very early epitopes, and we
show this reduces the estimate of the critical density.
Stochastic effects
Very early in infection, when infected cell numbers are small,
chains of transmission from cell to cell have a non-negligible
probability of going extinct. The presence of CTL, even at a
density insufficient to provide immunity once an infection reaches
a deterministic phase of growth, may increase the probability of
stopping virus growth very early in infection [42]. The use of high
inocula in vaccine trials may mask this potential protective effect.
Our calculation of the critical CTL density also assumes that the
population of infected cells has reached a stable age distribution,
which is a reasonable assumption following a small number of
rounds of infected cell growth, a timescale that is likely comparable
to that of activation of resident memory T cells. Explicit stochastic
simulations may be required to study the dependence of the
probability of early extinction on local CTL frequencies.
Are sterilizing levels of CTL physiologically possible?
One concern with T cell based vaccines is that protection may
only be possible with very high CTL densities, suggested by studies
of CD8 T cell protection against the liver stage of Malaria
infection [43], although in this system there may be significant
spatial constraints on the surveillance of liver tissue by CTL. If this
is the case, then according to the canonical model of a finite
homeostatic capacity for T cell memory, the use of such vaccines
may compromise the maintenance of existing memory T cell
populations. However, it may be possible to generate very large
numbers of CTL with prime-boost vaccination regimens without
substantially ablating immunity to other pathogens [44].
In summary, our studies suggest that while there are many
caveats with using models of CTL control of infected cell to
understand infection dynamics, knowledge of life-history strategies
may be important for refining our quantitative understanding of
how CTL can contribute to the control of acute infections.
Methods
All analyses were performed in R [45].
Supporting Information
Text S1 Mass-action killing and the interpretation of
the rate constant k. The interpretation of the rate constant k in
equation (1) in the text when cell numbers are described as either
dimensionless densities, as in the text, or as cells per unit volume.
(PDF)
Text S2 Modeling CTL killing with handling time and
virus epitope dynamics. A description of how the two models
discussed here derive from a single model of CTL killing that
incorporates both CTL-target handling time and the dynamics of
virus epitope expression.
(PDF)
Text S3 Derivation of the Lotka-Euler equation. Deriva-
tion of equation (16) for the growth rate of a population of infected
cells with a steady-state distribution of times since infection.
(PDF)
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